Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

NCT04778982 · clinicaltrials.gov ↗

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Difficulty in completing enrollment within the planned time

Conditions

HER2-positive Metastatic Breast Cancer

Interventions

DRUG: KN026 combined with Palbociclib and Fulvestrant

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd